Atrys Health Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Isabel Lozano Fernandez

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	0.4%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	2.4yrs

Actualizaciones recientes de la dirección

Recent updates

Atrys Health, S.A. (BME:ATRY) Shares Could Be 33% Above Their Intrinsic Value Estimate

Dec 11

CEO

Isabel Lozano Fernandez

no data

Permanencia

Ms. Isabel Lozano Fernandez serves as Chief Executive Officer and Executive Director at Atrys Health, S.A. Ms. Lozano Fernández served as Chief Executive Officer and Managing Director of PharmaMar, SA. Ms....

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Santiago De Torres Sanahuja	Executive Chairman	no data	sin datos	0.18% € 428.3k
Isabel Lozano Fernandez	CEO & Executive Director	no data	sin datos	0.44% € 1.0m
Antonio Baselga de la Vega	Director	no data	sin datos	sin datos
Jose Luis Enriquez		no data	sin datos	sin datos
Josep Echarri Torres	Director	no data	sin datos	sin datos
Jaime Cano Fernandez	Independent Director	no data	sin datos	0.030% € 71.4k
Jaime del Barrio Seoane	Independent Director	no data	sin datos	0.030% € 71.4k
Fernando de Lorenzo Lopez	Director	no data	sin datos	sin datos
Anabel Porta	Proprietary Director	2.4yrs	sin datos	sin datos
María Rosa Sans	Proprietary Director	2.4yrs	sin datos	sin datos
Aurora Cata Sala	Independent Director	2.4yrs	sin datos	0.020% € 47.6k
Manuel Maldonado	Proprietary Director	1.3yrs	sin datos	sin datos

2.4yrs

Permanencia media

Junta con experiencia: La junta directiva de ATRY no se considera experimentada (2.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Atrys Health Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Full year 2023 earnings released: €0.60 loss per share (vs €0.34 loss in FY 2022)

Consensus EPS estimates fall by 65%

Consensus EPS estimates fall by 25%

New minor risk - Share price stability

Now 23% undervalued after recent price drop

Arraigo Midco Sl acquired a 75% stake in Professional Group Conversia, S.L.U from Atrys Health, S.A. (BME:ATRY) for €35 million.

Price target decreased by 8.4% to €7.23

First half 2023 earnings released: €0.17 loss per share (vs €0.044 loss in 1H 2022)

New minor risk - Financial position

Is Atrys Health, S.A. (BME:ATRY) Trading At A 44% Discount?

New minor risk - Share price stability

The Returns At Atrys Health (BME:ATRY) Aren't Growing

Price target decreased by 15% to €8.85

Full year 2022 earnings released: €0.34 loss per share (vs €0.46 loss in FY 2021)

Atrys Health, S.A. acquired 70% stake in Initia Research.

Atrys Health, S.A. (BME:ATRY) acquired ChileRad for €10 million.

Returns On Capital Are Showing Encouraging Signs At Atrys Health (BME:ATRY)

Less than half of directors are independent

Price target decreased to €10.46

First half 2022 earnings released: EPS: €0 (vs €0.084 loss in 1H 2021)

Juan María Riberas Mera acquired a 5.432% stake in Atrys Health, S.A. (BME:ATRY) for €28 million.

Atrys Health, S.A. (BME:ATRY) agreed to acquire Significant Impact Systems SL for €94.47 million.

Less than half of directors are independent

Full year 2021 earnings: Revenues miss analyst expectations

Now 21% undervalued after recent price drop

Atrys Health (BME:ATRY) Might Have The Makings Of A Multi-Bagger

Price target increased to €11.39

Atrys Health, S.A. (BME:ATRY) signed an agreement to acquire Genetyca.

An unknown buyer acquired 5% stake in Atrys Health, S.A. (BME:ATRY) from Inversiones Industriales Serpis S.L.

Price target raised to €10.18

Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America

Did You Miss Atrys Health's (BME:ATRY) Whopping 387% Share Price Gain?

New 90-day high: €10.20

New 90-day high: €8.90

Atrys Health, S.A. (BME:ATRY) Shares Could Be 33% Above Their Intrinsic Value Estimate

Atrys Health, S.A. (BME:ATRY) acquired 91.7% stake in Grupo Lenitudes SGPS, SA from MCH Iberian Capital Fund III, FCR managed by MCH for €19.6 million.

New 90-day high: €7.86

Atrys Health, S.A. (BME:ATRY) acquired Instituto de Estudios Celulares y Moleulares S.A.

Atrys Health, S.A. (BME:ATRY) acquired Axismed Gestão Preventiva da Saúde S.A. from Telefónica Digital España, S.L. for BRL 14 million.

Atrys Health, S.A. announced that it has received €35.2 million in funding

CEO

Permanencia

Miembros de la Junta

Permanencia media